THERAVANCE BIOPHARMA INC's ticker is TBPH and the CUSIP is G8807B106. A total of 81 filers reported holding THERAVANCE BIOPHARMA INC in Q1 2016. The put-call ratio across all filers is 1.00 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $509,248 | -16.6% | 59,009 | 0.0% | 0.01% | -16.7% |
Q2 2023 | $610,743 | -4.6% | 59,009 | 0.0% | 0.01% | 0.0% |
Q1 2023 | $640,248 | -3.3% | 59,009 | 0.0% | 0.01% | -14.3% |
Q4 2022 | $662,081 | +10.7% | 59,009 | 0.0% | 0.01% | 0.0% |
Q3 2022 | $598,000 | +11.8% | 59,009 | 0.0% | 0.01% | +16.7% |
Q2 2022 | $535,000 | -5.1% | 59,009 | 0.0% | 0.01% | +20.0% |
Q1 2022 | $564,000 | -13.5% | 59,009 | 0.0% | 0.01% | 0.0% |
Q4 2021 | $652,000 | +49.2% | 59,009 | 0.0% | 0.01% | +66.7% |
Q3 2021 | $437,000 | -49.0% | 59,009 | 0.0% | 0.00% | -50.0% |
Q2 2021 | $857,000 | -28.8% | 59,009 | 0.0% | 0.01% | -25.0% |
Q1 2021 | $1,204,000 | +14.8% | 59,009 | 0.0% | 0.01% | -11.1% |
Q4 2020 | $1,049,000 | -23.9% | 59,009 | -36.8% | 0.01% | -40.0% |
Q3 2020 | $1,379,000 | -29.6% | 93,300 | 0.0% | 0.02% | -31.8% |
Q2 2020 | $1,958,000 | -9.2% | 93,300 | 0.0% | 0.02% | -24.1% |
Q1 2020 | $2,156,000 | -10.8% | 93,300 | 0.0% | 0.03% | +31.8% |
Q4 2019 | $2,416,000 | +33.0% | 93,300 | 0.0% | 0.02% | +29.4% |
Q3 2019 | $1,817,000 | +19.2% | 93,300 | 0.0% | 0.02% | +21.4% |
Q2 2019 | $1,524,000 | -27.9% | 93,300 | 0.0% | 0.01% | -22.2% |
Q1 2019 | $2,115,000 | -11.4% | 93,300 | 0.0% | 0.02% | -14.3% |
Q4 2018 | $2,388,000 | -21.7% | 93,300 | 0.0% | 0.02% | 0.0% |
Q3 2018 | $3,048,000 | +44.0% | 93,300 | 0.0% | 0.02% | +40.0% |
Q2 2018 | $2,116,000 | -6.5% | 93,300 | 0.0% | 0.02% | -6.2% |
Q1 2018 | $2,263,000 | -13.0% | 93,300 | 0.0% | 0.02% | -5.9% |
Q4 2017 | $2,602,000 | -18.6% | 93,300 | 0.0% | 0.02% | -19.0% |
Q3 2017 | $3,195,000 | -14.0% | 93,300 | 0.0% | 0.02% | -16.0% |
Q2 2017 | $3,717,000 | -2.3% | 93,300 | -9.7% | 0.02% | 0.0% |
Q1 2017 | $3,804,000 | +15.5% | 103,300 | 0.0% | 0.02% | +19.0% |
Q4 2016 | $3,293,000 | -23.5% | 103,300 | -13.0% | 0.02% | -25.0% |
Q3 2016 | $4,305,000 | -28.6% | 118,800 | -55.3% | 0.03% | -30.0% |
Q2 2016 | $6,029,000 | -11.6% | 265,700 | -26.7% | 0.04% | -7.0% |
Q1 2016 | $6,819,000 | +1.8% | 362,700 | -11.2% | 0.04% | +7.5% |
Q4 2015 | $6,697,000 | +18.6% | 408,600 | -20.5% | 0.04% | +33.3% |
Q3 2015 | $5,646,000 | -10.9% | 513,700 | +5.5% | 0.03% | +11.1% |
Q2 2015 | $6,337,000 | -27.8% | 486,700 | -3.8% | 0.03% | -18.2% |
Q1 2015 | $8,777,000 | +2.4% | 505,900 | -11.9% | 0.03% | +10.0% |
Q4 2014 | $8,570,000 | +291.3% | 574,400 | +504.6% | 0.03% | +328.6% |
Q3 2014 | $2,190,000 | -32.1% | 95,000 | -6.2% | 0.01% | -30.0% |
Q2 2014 | $3,227,000 | – | 101,228 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Link Fund Solutions Ltd | 5,251,349 | $135,459,000 | 69.86% |
Chescapmanager LLC | 949,006 | $24,570,000 | 3.61% |
Baupost Group | 9,309,168 | $241,014,000 | 2.66% |
Rock Springs Capital Management LP | 655,200 | $16,963,000 | 0.54% |
Rubric Capital Management LP | 173,400 | $4,489,000 | 0.51% |
Newtyn Management, LLC | 173,300 | $4,487,000 | 0.41% |
NJ State Employees Deferred Compensation Plan | 38,142 | $988,000 | 0.17% |
King Wealth Management Group | 22,500 | $583,000 | 0.15% |
Virtus ETF Advisers LLC | 29,216 | $756,000 | 0.12% |
JACOBS LEVY EQUITY MANAGEMENT, INC | 452,615 | $11,718,000 | 0.12% |